442: EVALUATION OF TOCILIZUMAB FOR COVID-19 TREATMENT IN THE INTENSIVE CARE UNIT.

B Introduction: b Tocilizumab is recognized as a safe and efficacious treatment option for critically ill patients with COVID-19. C-reactive protein (CRP), ferritin, and lactate dehydrogenase (LDH) were reviewed and compared to institutional criteria for use. B Conclusions: b Critically ill patients receiving tocilizumab for COVID-19 treatment have high rates of mortality despite early use upon ICU admission. [Extracted from the article]